The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PORTOS gene signature as a predictor of risk of adverse events after dose-escalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126.
 
Karen Hoffman
Employment - MD Anderson Cancer Center
Research Funding - Janssen (Inst); Varian Medical Systems (Inst)
 
Sophia Kamran
Employment - Sanofi (I)
Honoraria - Medscape; Varian Medical Systems
 
Hyunnam Ryu
No Relationships to Disclose
 
James Proudfoot
Employment - Veracyte
Stock and Other Ownership Interests - Veracyte
 
Elai Davicioni
Employment - Veracyte
 
Paul Nguyen
Stock and Other Ownership Interests - Nanocan Therapeutics; Reversal Therapeutics; Stratagen Bio; Telerad Oncology; Volatilyx (I)
Consulting or Advisory Role - AIQ Solutions; Bayer; Blue Earth Diagnostics; Boston Scientific; Janssen Oncology; Myovant Sciences; Nanocan Therapeutics; Novartis; Theranano
Research Funding - Astellas Pharma; Bayer; Janssen
Patents, Royalties, Other Intellectual Property - Wife has a patent on volatile diagnostics of infections (I)
 
Stephanie Pugh
Research Funding - Millennium (Inst); Pfizer (Inst)
 
Daniel Spratt
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Blue Earth Diagnostics; Boston Scientific; Janssen Oncology; Novartis; Pfizer
Research Funding - Janssen (Inst)
(OPTIONAL) Uncompensated Relationships - NCCN
 
Jeff Michalski
Leadership - American Society of Therapeutic Radiation Oncology
Travel, Accommodations, Expenses - American Society of Therapeutic Radiation Oncology
 
Matthew Parliament
No Relationships to Disclose
 
Ian Dayes
Honoraria - Verity Pharmaceuticals
 
Rohann Correa
No Relationships to Disclose
 
John Robertson
No Relationships to Disclose
 
Elizabeth Gore
No Relationships to Disclose
 
Desiree Doncals
Research Funding - PreludeDx; Summa Health System
 
Eric Vigneault
No Relationships to Disclose
 
Luis Souhami
No Relationships to Disclose
 
Felix Feng
Stock and Other Ownership Interests - Artera; Bluestar Genomics; Serimmune
Consulting or Advisory Role - Artera; Astellas Pharma; Bayer; BlueStar Genomics; Bristol Myers Squibb; Bristol Myers Squibb (BMS); Exact Sciences; Foundation Medicine; Janssen Biotech; Myovant Sciences; Novartis; POINT Biopharma; Roivant; SerImmune; Tempus; Varian Medical Systems
Research Funding - Zenith Epigenetics
 
Phuoc Tran
Honoraria - Reflexion Medical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Health; Dendreon; GenomeDx; Janssen; Lantheus Medical Imaging; Myovant Sciences; Noxopharm; Reflexion Medical; Reflexion Medical; Regeneron
Research Funding - Astellas Pharma (Inst); Bayer Health (Inst); Reflexion Medical (Inst)
Patents, Royalties, Other Intellectual Property - Compounds and Methods of Use in Ablative Radiotherapy. Patent filed 3/9/2012. PCT/US2012/028475. PCT/WO/2012/122471.
Travel, Accommodations, Expenses - Reflexion Medical
 
Shuang Zhao
Employment - Artera (I)
Stock and Other Ownership Interests - Exact Sciences (I)
Patents, Royalties, Other Intellectual Property - Patent applications pending (Inst); Patent applications pending licensed to Veracyte (Inst)